Review: Preventing diabetes in the obese: the XENDOS study and its context

Abstract

This article reviews the evidence, from both observational epidemiology and randomised clinical trials, that lifestyle modification as well as anti-diabetic drugs can reduce or delay the development of diabetes in overweight and obese patients with IGT. Particular consideration is given to the recently published XENDOS study which showed that the combination of orlistat and lifestyle changes over four years is safe and well tolerated, results in a weight loss of about six kg and reduces the risk of developing diabetes by 45% in obese IGT patients. Thus, addition of orlistat to lifestyle intervention has a greater diabetes-preventing effect than lifestyle modification alone.

Keywords

diabetes obesity prevention lifestyle drug treatment.

Get full access to this article

View all access options for this article.

References

World Health Organization. Obesity: Preventing and managing the global epidemic. WHO Technical Report Series 894. World Health Organization, Geneva, 2000.

Diabetes Atlas, second edition. IDF 2003. www.idf.org/e-atlas

Powers AC Diabetes mellitus. In: Braunwald E , Fauci AS , Kasper DL , Hauser SL , Longo DL , Jameson JL eds. Harrison's principles of internal medicine 1 5th edition. New York: McGraw-Hill, 2001:2109-37.

Eriksson J. , Lindström J. , Valle T. et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Diabetologia 1999;42:793-801.

Zimmet P. , Alberti Kgmm , Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.

Unwin N. , Shaw J. , Zimmet P. et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.

Wolf AM , Colditz AG Current estimates of the economic cost of obesity in the United States . Obes Res 1998;6:97-106.

Williamson DF , Thompson TJ , Thun M. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.

Pinkney JH , Sjöström CD , Gale EAM.

Should surgeons treat diabetes in severely obese people?

Lancet 2001;357:1357-9.

10.

MacDonald KG , Long SD , Swanson MS et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus . J Gastrointest Surg 1997;1:243-20.

11.

Poires WJ , Swanson MS , MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset

12.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

13.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

14.

Joslin EP The prevention of diabetes mellitus. JAMA 1921;76:79-84.

15.

World Health Organization. Prevention of diabetes mellitus. WHO Technical Report Series 844. World Health Organization, Geneva, 1994.

16.

Pinkney J. Prevention and cure of type 2 diabetes. BMJ 2002;325:232-3.

17.

Eriksson KF , Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991;34:891-8.

18.

Pan XR , Li GW , Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997;20:537-44.

19.

Hu FB , Manson JE , Stampfer MJ et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.

20.

Toumilehto J. , Lindström J. , Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.

21.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med 2002;346:393-403.

22.

Heymsfield SB , Segal KR , Hauptman J. et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.

23.

Torgerson JS , Hauptman J. , Boldrin MN et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients . Diabetes Care 2004;27:155-61.

24.

Chiasson Jl , Josse RG , Gomis R. et al. Acarbose for the prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial . Lancet 2002; 359:2072-7.

25.

Buchanan TA , Xiang AH , Peters RK et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.

26.

Sjöström CD , Peltonen M. , Wedel H. et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension . Hypertension 2000;36:20-5.

27.

Sjöström L. Surgical intervention as a strategy for treatment of obesity. Endocrine 2000;13:213-30.

28.

Long SD , O'Brien K. , MacDonald KG et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. Diabetes Care 1994;17:372-5.

29.

Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-34.

30.

Chiasson JL , Gomis R. , Hanefeld M. et al. The STOP-NIDDM trial. An interventional study on the efficacy of an α-glucosidase inhibitor to prevent type 2 I diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 1998;21: 1720-5.

31.

Chiasson JL , Josse RG , Gomis R. et al. Acarbose treatment and risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003;290:486-94.

32.

Azen SP , Berkowitz K. , Kjos S. et al. TRIPOD: a randomised placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-31.

33.

Sparre Hermann L. , Wiernsperger N. Impaired glucose tolerance and metformin: clinical and mechanistic aspects. Br J Diabetes Vasc Dis 2002;2: 177-83.

34.

Parker JC Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 2002;54:1173-97.

35.

Hauptman JB , Jeunet FS , Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin) . Am J Clin Nutr 1992;55:309-13.

36.

Torgerson JS , Arlinger K. , Käppi M. et al. Principles for enhanced recruitment of subjects in a large clinical trial: The XENDOS study experience. Control Clin Trials 2001;22:515-25.

37.

Richard JL , Sultan A. , Daures JP et al. Diagnosis of diabetes mellitus and intermediate glucose abnormalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabet Med 2002;19:292-9.

38.

Borch-Johnsen K.

IGT and IFG. Time for revision?

Diabet Med 2002;19: 707.

39.

The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.

40.

Wylie G. , Hungin APS , Neely J. Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions. BMJ 2002;324:1190-2.

41.

Miles JM , Leiter L. , Hollander P. et al. Effects of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8.